Announcement of Chengdu Olin Biotechnology Co., Ltd. on voluntary disclosure of the approval of Phase I clinical trial of oral recombinant Helicobacter pylori vaccine (E. coli) in Australia.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.